Carbylan Therapeutics (CBYL) Tops Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Carbylan Therapeutics Announces Third Quarter 2015 Financial Results
November 11, 2015 7:30 AM ESTPALO ALTO, Calif., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ: CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies, today announced financial results for the third quarter ended September 30, 2015.
"Carbylan remains focused on the successful execution of our phase 3 clinical development program for our lead product candidate, Hydros-TA," commented David Renzi, President and CEO of Carbylan Therapeutics. "Importantly, our fully enrolled COR1.1 trial is progressing as planned with data anticipated in the first quarter of 2016. We believe these results will provide further validation of our innovative... More
Carbylan Therapeutics Announces Third Quarter 2015 Financial Results
November 11, 2015 7:30 AM ESTPALO ALTO, Calif., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ: CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies, today announced financial results for the third quarter ended September 30, 2015.
"Carbylan remains focused on the successful execution of our phase 3 clinical development program for our lead product candidate, Hydros-TA," commented David Renzi, President and CEO of Carbylan Therapeutics. "Importantly, our fully enrolled COR1.1 trial is progressing as planned with data anticipated in the first quarter of 2016. We believe these results will provide further validation of our innovative... More
